XURIDEN ™
Clinical pharmacology
| Initial U.S. Approval: 2015 Mechanism of Action: Uridine triacetate is an acetylated form of uridine. Following oral administration, uridine triacetate is deacetylated by nonspecific esterases present throughout the body, yielding uridine in the circulation. XURIDEN provides uridine in the systemic circulation of patients with hereditary orotic aciduria who cannot synthesize adequate quantities of uridine due to a genetic defect in uridine nucleotide synthesis. |
Indications and usage
| INDICATIONS AND USAGE: XURIDEN™ is indicated for the treatment of hereditary orotic aciduria. |
Dosage and administration
| Drug UPDATES: XURIDEN ™ - uridine triacetate granule [Drug information / PDF] Click link for the latest monograph Dosing: Click (+) next to Dosage and Administration section (drug info link) |
How supplied
| HOW SUPPLIED: Oral granules: 2 grams of orange-flavored oral granules (95% w/w) in single-use packets |
Reference
| [Drug information / PDF] Click link for the latest monograph |
Reference(s)
National Institutes of Health, U.S. National Library of Medicine, DailyMed Database.
Provides access to the latest drug monographs submitted to the Food and Drug Administration (FDA). Please review the latest applicable package insert for additional information and possible updates. A local search option of this data can be found here.
